Rational design of M2e-FP conserved epitope-based universal influenza A vaccines
Rational design of M2e-FP conserved epitope-based universal influenza A vaccines
批准号:
8210840
负责人:
Lanying Du
金额:
$8.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-15 至 2012-12-31
关键词:
AdultAnimalsAntibodiesAntibody FormationAntigensBudgetsCellsCenters for Disease Control and Prevention (U.S.)Chimeric ProteinsCollaborationsConserved SequenceDetectionDevelopmentDisease OutbreaksEbola virusEnhancersEpidemicEpitopesExtracellular DomainFamily suidaeFc ImmunoglobulinsFutureGoalsHIVHemagglutininHong KongHumanImmuneImmune responseImmunityImmunizationImmunoglobulin GInbred BALB C MiceInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A virusLicensingLifeLinkMediatingMembrane ProteinsMethodsMicrobiologyMusOryctolagus cuniculusPanicParentsPeptidesPlant ResinsPropertyProteinsPublic HealthReagentRecombinant ProteinsRecombinant VaccinesRecombinantsRegimenReportingResearchResearch ProposalsResourcesSARS coronavirusSerumSplenocyteStaphylococcal protein A-sepharoseStructure of parenchyma of lungTechniquesTestingUniversitiesVaccinatedVaccinationVaccine DesignVaccinesViralVirusVirus DiseasesVirus Replicationantibody-dependent cell cytotoxicitybasedesignexperienceimmunogenicityin vivoinfluenza epidemicinfluenza outbreakinfluenza virus vaccineinfluenzavirusmouse modelneutralizing antibodynovelpandemic diseasepandemic influenzapreventprogramsprotein expressionpublic health relevanceresearch studyseasonal influenzaswine fluvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The recent global outbreak of influenza A caused by a novel swine-origin H1N1 influenza A virus (S-OIV) has led to a growing concern regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses because the currently licensed seasonal influenza vaccines fail to produce cross-protection against the newly emerging influenza A viruses (IAVs). Therefore, development of a safe and effective vaccine against divergent IAVs, especially those causing current and future influenza pandemics, is urgently needed. We and others have reported that the extracellular domain of matrix protein 2 (M2e) and the fusion peptide (FP) of the hemagglutinin-2 (HA2) that contain highly conserved epitopes can induce strong humoral and cellular immune responses and broad protection against IAVs. Our preliminary studies also showed that the recombinant HA protein fused to Fc fragment of IgG as an immune enhancer could induce strong cross-neutralizing antibody responses and cross- protection against various strains of H5N1 viruses. We thus hypothesize that a recombinant protein containing the highly conserved epitopes in M2e and FP fused to Fc may elicit potent humoral and cellular immune responses, including the neutralizing antibodies, and induce cross-protection against divergent IAVs, including current epidemic H1N1 and HPAI H5N1 strains, and other isolates that might cause future pandemics. The specific aims of this proposal are: (1) to design an influenza vaccine containing conserved epitopes in M2e and FP of IAV (M2e-FP) fused with Fc immune enhancer (M2e-FP-Fc) and use M2e-FP, FP-Fc and M2e-Fc as controls; (2) to immunize mice and rabbits with these antigens, alone or in combination (e.g., M2e-FP-Fc + FP-Fc), and to assess specific humoral and cellular immune responses and neutralizing antibodies in the vaccinated animals; (3) to evaluate the in vivo protective immunity against IAV challenge in the immunized mouse models. The long-term goal of the proposed study is to develop a universal influenza A vaccine against divergent IAVs, including those causing future influenza pandemics.
PUBLIC HEALTH RELEVANCE: The current H1N1 influenza pandemic (commonly known as the "swine flu") and the potential outbreak of H5N1 influenza in the future pose serious threats to public health worldwide. The goal of this proposed study is to design and develop a "universal" vaccine for influenza A viruses based on the conserved sequences of viral surface proteins linked with a molecule to enhance immunogenicity of the antigens and this influenza vaccine is expected to be effective and safe for human use for preventing influenza epidemics in the future.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/rmv.1729
发表时间:
2012-11
期刊:
REVIEWS IN MEDICAL VIROLOGY
影响因子:
11.1
作者:
[Du, Lanying, Li, Ye, Gao, Jimin, Zhou, Yusen, Jiang, Shibo]
通讯作者:
Jiang, Shibo
DOI:
10.1371/journal.pone.0053568
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S]
通讯作者:
Jiang S
Project 2: Nanobodies as Novel Entry Inhibitors of Pandemic Viruses
-
批准号:10522811
-
项目类别:
-
资助金额:$377.42万
-
财政年份:2022
-
负责人:Lanying Du
-
依托单位:
Rational design and evaluation of novel mRNA vaccines against MERS-CoV
-
批准号:10335159
-
项目类别:
-
资助金额:$74.22万
-
财政年份:2021
-
负责人:Lanying Du
-
依托单位:
Rational design and evaluation of novel mRNA vaccines against MERS-CoV
-
批准号:10410839
-
项目类别:
-
资助金额:$55.5万
-
财政年份:2021
-
负责人:Lanying Du
-
依托单位:
Structure-based design of coronavirus subunit vaccines
-
批准号:10397563
-
项目类别:
-
资助金额:$79.6万
-
财政年份:2021
-
负责人:Lanying Du
-
依托单位:
Structure-based design of coronavirus subunit vaccines
-
批准号:10415747
-
项目类别:
-
资助金额:$72.9万
-
财政年份:2021
-
负责人:Lanying Du
-
依托单位:
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
-
批准号:10411118
-
项目类别:
-
资助金额:$76.61万
-
财政年份:2020
-
负责人:Lanying Du
-
依托单位:
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
-
批准号:10168173
-
项目类别:
-
资助金额:$83.27万
-
财政年份:2020
-
负责人:Lanying Du
-
依托单位:
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
-
批准号:10662297
-
项目类别:
-
资助金额:$75.93万
-
财政年份:2020
-
负责人:Lanying Du
-
依托单位:
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
-
批准号:10456313
-
项目类别:
-
资助金额:$75.97万
-
财政年份:2020
-
负责人:Lanying Du
-
依托单位:
A novel and effective nanobody to prevent and treat Zika virus infection
-
批准号:9920081
-
项目类别:
-
资助金额:$26.7万
-
财政年份:2019
-
负责人:Lanying Du
-
依托单位:
Structure-based design of coronavirus subunit vaccines
-
批准号:9914088
-
项目类别:
-
资助金额:$83.92万
-
财政年份:2018
-
负责人:Lanying Du
-
依托单位:
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination
-
批准号:9753893
-
项目类别:
-
资助金额:$55.55万
-
财政年份:2016
-
负责人:Lanying Du
-
依托单位:
A novel nanobody with good druggability to prevent and treat MERS-CoV infection
-
批准号:9226400
-
项目类别:
-
资助金额:$26.34万
-
财政年份:2016
-
负责人:Lanying Du
-
依托单位:
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMC
-
批准号:8619937
-
项目类别:
-
资助金额:$21.22万
-
财政年份:2013
-
负责人:Lanying Du
-
依托单位:
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMC
-
批准号:8786444
-
项目类别:
-
资助金额:$25.37万
-
财政年份:2013
-
负责人:Lanying Du
-
依托单位:
Rational design of M2e-FP conserved epitope-based universal influenza A vaccines
-
批准号:8048662
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2011
-
负责人:Lanying Du
-
依托单位:
海外基金